aTyr Pharma, Inc. (NASDAQ:LIFE) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The brokerage presently has a $3.50 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target indicates a potential downside of 5.41% from the company’s current price.

According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “

Other research analysts have also issued reports about the company. Piper Jaffray Companies started coverage on aTyr Pharma in a research report on Thursday, September 7th. They issued an “overweight” rating and a $7.00 target price on the stock. BMO Capital Markets set a $4.00 target price on aTyr Pharma and gave the stock a “hold” rating in a research report on Tuesday, August 15th. Finally, ValuEngine lowered aTyr Pharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $4.27.

aTyr Pharma (NASDAQ:LIFE) traded up 12.12% during midday trading on Wednesday, reaching $3.70. The company’s stock had a trading volume of 219,556 shares. The company has a 50 day moving average price of $3.26 and a 200 day moving average price of $3.45. The firm’s market cap is $88.20 million. aTyr Pharma has a 1-year low of $2.10 and a 1-year high of $4.45.

aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.06. On average, equities research analysts expect that aTyr Pharma will post ($2.18) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/17/atyr-pharma-inc-life-upgraded-by-zacks-investment-research-to-buy.html.

In related news, CEO John Mendlein acquired 37,736 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were bought at an average cost of $2.65 per share, with a total value of $100,000.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul Schimmel acquired 94,336 shares of the business’s stock in a transaction on Thursday, August 31st. The stock was bought at an average cost of $2.65 per share, for a total transaction of $249,990.40. Following the completion of the transaction, the director now directly owns 40,440 shares of the company’s stock, valued at $107,166. The disclosure for this purchase can be found here. Company insiders own 33.30% of the company’s stock.

An institutional investor recently raised its position in aTyr Pharma stock. Renaissance Technologies LLC raised its stake in aTyr Pharma, Inc. (NASDAQ:LIFE) by 1.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,800 shares of the biotechnology company’s stock after purchasing an additional 700 shares during the quarter. Renaissance Technologies LLC owned about 0.16% of aTyr Pharma worth $136,000 at the end of the most recent quarter. 46.66% of the stock is owned by institutional investors and hedge funds.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.